Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
96 hedge funds and large institutions have $1.03B invested in Aegerion Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 39 increasing their positions, 27 reducing their positions, and 16 closing their positions.
86% more capital invested
Capital invested by funds: $554M → $1.03B (+$476M)
44% more repeat investments, than reductions
Existing positions increased: 39 | Existing positions reduced: 27
0% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 16
1% less funds holding
Funds holding: 97 → 96 (-1)
21% less call options, than puts
Call options by funds: $4.27M | Put options by funds: $5.39M
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$14.4M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
+$9.23M |
| 3 |
Morgan Stanley
New York
|
+$6.47M |
| 4 |
SCM
Scopia Capital Management
New York
|
+$4.9M |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$4.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadfin Capital
New York
|
-$9.48M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$4.29M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.89M |
| 4 |
AI
Advent International
Boston,
Massachusetts
|
-$3.76M |
| 5 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$3.6M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SCA
101
Secor Capital Advisors
New York
| – | -$369K | -19,469 | Closed |
|
|
PP
102
Paloma Partners
Greenwich,
Connecticut
| – | -$319K | -16,800 | Closed |
|
103
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$185K | -9,739 | Closed |
|
|
FMA
104
FNY Managed Accounts
New York
| – | -$94.8K | -5,000 | Closed |
|
|
FM
105
Forward Management
San Francisco,
California
| – | -$87K | -4,600 | Closed |
|
|
FCE
106
Fiera Capital (Europe)
Grand Cayman,
Cayman Islands
| – | -$83K | -4,362 | Closed |
|
|
TRCT
107
Tower Research Capital (TRC)
New York
| – | -$30K | -1,580 | Closed |
|
108
Invesco
Atlanta,
Georgia
| – | -$5K | -287 | Closed |
|
|
JG
109
Jefferies Group
New York
| – | -$2K | -90 | Closed |
|
|
GT
110
Glenmede Trust
Philadelphia,
Pennsylvania
| – | +$1.16K | +65 | New |
|
AEGR Hedge Fund Activity: Q3 2015 in Review
96 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q3 2015, worth a combined $1.03B — up 86% from $554M a quarter earlier.
Fund positioning in AEGR was balanced in Q3 2015: 16 funds opened new positions, 16 closed out, 39 added to existing stakes and 27 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $14.4M. The largest seller was Broadfin Capital, cutting an estimated $9.48M.
- 96 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q3 2015, down from 97 in Q2 2015.
- Funds reported $1.03B of Aegerion Pharmaceuticals stock for Q3 2015, up 86% quarter-over-quarter.
- 16 funds opened new Aegerion Pharmaceuticals positions in Q3 2015 and 16 closed out, a net change of 0 holders.
- The largest Aegerion Pharmaceuticals buyer in Q3 2015 was Avoro Capital Advisors, an estimated $14.4M added.
- The largest Aegerion Pharmaceuticals seller in Q3 2015 was Broadfin Capital, an estimated $9.48M sold.
Based on aggregated 13F filings for Q3 2015.